Adoption and Implementation of Medications in Addiction Treatment Programs
暂无分享,去创建一个
[1] Alison L. Koch,et al. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. , 2006, Drug and alcohol dependence.
[2] Lori J. Ducharme,et al. State policy influence on the early diffusion of buprenorphine in community treatment programs , 2008, Substance abuse treatment, prevention, and policy.
[3] W. Kissin,et al. Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence , 2006, Journal of addictive diseases.
[4] Dennis McCarty,et al. Research to practice: adoption of naltrexone in alcoholism treatment. , 2003, Journal of substance abuse treatment.
[5] T. Mark,et al. Understanding US addiction physicians' low rate of naltrexone prescription. , 2003, Drug and alcohol dependence.
[6] N. Brown,et al. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. , 2004 .
[7] W. Ling,et al. Medications development: successes and challenges. , 2005, Pharmacology & therapeutics.
[8] C. Thomas,et al. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. , 2008, Psychiatric services.
[9] D. McCarty,et al. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. , 2007, Journal of substance abuse treatment.
[10] Lori J. Ducharme,et al. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. , 2006, Journal of substance abuse treatment.
[11] Lori J. Ducharme,et al. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. , 2007, Drug and alcohol dependence.
[12] John Fitzgerald,et al. Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach. , 2009, Psychological services.
[13] J. Chilingerian,et al. Substance Abuse Treatment Organizations as Mediators of Social Policy: Slowing the Adoption of a Congressionally Approved Medication , 2008, The Journal of Behavioral Health Services & Research.
[14] Lori J. Ducharme,et al. The Use of Antidepressant Medications in Substance Abuse Treatment: The Public-Private Distinction, Organizational Compatibility, and the Environment∗ , 2007, Journal of health and social behavior.
[15] C. Thomas,et al. Factors Determining How Early Adopter Physicians Use Buprenorphine in Treatment , 2007, Journal of addiction medicine.
[16] Lori J. Ducharme,et al. Counselor attitudes toward pharmacotherapies for alcohol dependence. , 2009, Journal of studies on alcohol and drugs.
[17] T. Mark,et al. Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. , 2003, Value in Health.
[18] Lori J. Ducharme,et al. Organizational Predictors of Pharmacological Innovation Adoption: The Case of Disulfiram , 2005 .
[19] Carolyn J. Heinrich,et al. Role of state policies in the adoption of naltrexone for substance abuse treatment. , 2007, Health services research.
[20] Joffre Swait,et al. Using stated preference and revealed preference modeling to evaluate prescribing decisions. , 2004, Health economics.
[21] Lori J. Ducharme,et al. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. , 2005, Journal of substance abuse treatment.
[22] C. Horgan,et al. Availability of addiction medications in private health plans. , 2008, Journal of substance abuse treatment.
[23] Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. , 2009, Journal of substance abuse treatment.
[24] Adoption of naltrexone to treat alcohol dependence. , 2005, Journal of substance abuse treatment.
[25] Lori J. Ducharme,et al. Trends in the Adoption of Medications for Alcohol Dependence , 2006, Journal of clinical psychopharmacology.
[26] P. Friedmann,et al. Top Manager Effects on Buprenorphine Adoption in Outpatient Substance Abuse Treatment Programs , 2010, The Journal of Behavioral Health Services & Research.
[27] Lori J. Ducharme,et al. Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. , 2007, Journal of substance abuse treatment.
[28] H. Knudsen,et al. Modeling the use of innovations in private treatment organizations: the role of absorptive capacity. , 2004, Journal of substance abuse treatment.
[29] P. Roman,et al. Adoption and implementation of new technologies in substance abuse treatment. , 2002, Journal of substance abuse treatment.
[30] C. Cunningham,et al. Factors affecting willingness to provide buprenorphine treatment. , 2009, Journal of substance abuse treatment.